Myomo Inc (MYO)
XASE:MYO
Want to see MYO full AI Analyst Report?
MYO Stock Chart & Stats
$0.86
-$0.13(-1.86%)
At close: 4:00 PM EST
$0.86
-$0.13(-1.86%)
Day’s Range― - ―
52-Week Range$0.61 - $3.39
Previous CloseN/A
Volume192.17K
Average Volume (3M)328.72K
Market Cap
$32.42M
Enterprise Value$42.91M
Total Cash (Recent Filing)$15.70M
Total Debt (Recent Filing)$18.96M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding38,638,653
10 Day Avg. Volume423,107
30 Day Avg. Volume328,721
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.34
Price to Sales (P/S)0.93
P/FCF Ratio-2.34
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit1.58
Enterprise Value/Ebitda-3.37
Forecast
1Y Price Target
$4.32Price Target Upside402.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$44.21M
Bulls Say, Bears Say
Bulls Say
Commercial And International ExpansionPlanned international commercialization and expansion of the commercial team focused on the MyoPro targets growth across orthotics and prosthetics channels and could lift sales in new markets.
Recurring Patient Channels And Margin ImprovementA strategic shift toward recurring patient sources and the MyoConnect referral program is building a growing patient pipeline, lowering cost per patient and supporting improved gross margins.
Reimbursement ExpansionA favorable Medicare decision expanded reimbursement coverage for the MyoPro, substantially enlarging the addressable patient population and supporting higher adoption potential.
Bears Say
Analyst Conflicts Of InterestPotential conflicts of interest at Ascendiant Capital Markets LLC may undermine the perceived objectivity of analyst coverage and create uncertainty around the credibility of positive reports.
Execution, Regulatory And IP RisksAnalyst-identified risks—covering commercial execution, clinical development setbacks, financial strain, regulatory hurdles, and intellectual property disputes—could materially impede growth and valuation.
Lowered Guidance And Estimate CutsManagement issued revenue guidance below analyst expectations, prompting downward revisions to revenue and earnings estimates and reducing the price target, which raises near-term downside risk.
Myomo News
MYO FAQ
What was Myomo Inc’s price range in the past 12 months?
Myomo Inc lowest stock price was $0.60 and its highest was $3.39 in the past 12 months.
What is Myomo Inc’s market cap?
Myomo Inc’s market cap is $32.42M.
When is Myomo Inc’s upcoming earnings report date?
Myomo Inc’s upcoming earnings report date is Aug 11, 2026 which is in 82 days.
How were Myomo Inc’s earnings last quarter?
Myomo Inc released its earnings results on May 07, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.114 by $0.044.
Is Myomo Inc overvalued?
According to Wall Street analysts Myomo Inc’s price is currently Undervalued.
Does Myomo Inc pay dividends?
Myomo Inc does not currently pay dividends.
What is Myomo Inc’s EPS estimate?
Myomo Inc’s EPS estimate is -0.1.
How many shares outstanding does Myomo Inc have?
Myomo Inc has 38,638,653 shares outstanding.
What happened to Myomo Inc’s price movement after its last earnings report?
Myomo Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.114. Following the earnings report the stock price went down -5.052%.
Which hedge fund is a major shareholder of Myomo Inc?
Currently, no hedge funds are holding shares in MYO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myomo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.32 (402.33% Upside)
$4.32 (402.33% Upside)
Blogger Sentiment
Bullish
MYO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 62.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $278.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.32%
12-Months-Change
Fundamentals
Return on Equity
-114.87%
Trailing 12-Months
Asset Growth
-10.07%
Trailing 12-Months
Company Description
Myomo Inc
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
MYO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights steady, incremental progress: modest top-line growth (Q1 revenue +3%), improved gross margin (+100 bps), lower operating expenses (-1%), improved adjusted EBITDA (negative $2.3M vs negative $2.8M), strong shifts toward recurring revenue (49% of revenue vs 25% prior year), and robust international and O&P channel growth (international +53% YoY; U.S. O&P +79% YoY). Management provided constructive operational updates including payer contracting (covered lives up to 158M), product advances (mobile app reducing material costs ~10%, MyoPro 3 development), and a growing referral network (150+ rehab facilities, Autoboc partnership). Lowlights include continued net losses, dependency on a multi-quarter revenue cycle, macro pressures in Medicare Advantage and a decline in Medicare Part B dollar contribution, and some short-term margin pressure from higher on-site fitting costs. Overall, positive operational momentum and improving financial metrics outweigh remaining profitability and execution risks.View all MYO earnings summariesMYO Stock 12 Month Forecast
Average Price Target
$4.32
▲(402.33% Upside)
Technical Analysis
Electrocore
―
Modular Medical
―
Vicarious Surgical
―
Adagio Medical Holdings
―
Inspira Technologies Oxy BHN
―
Ownership Overview
13.75% Insiders
5.66% Mutual Funds
10.88% Other Institutional Investors
62.89% Public Companies and
Individual Investors